This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study used two designs. A retrospective comparative study with historical controls was employed to carry out a between-group comparison analysis, while a within-group comparison study was undertaken to compare TNS patients before and after receiving TNS treatment. The sub-analysis of the younger patients was also a within-group analysis. The study was multi-centred, with data being collected from 8 sites. The follow-up period was 2 years for TNS patients (one year before and one year after TNS treatment was administered), and 1 year for patients who did not receive TNS treatment. The authors did not report any loss to follow-up. The patients were matched in terms of age, gender, lung function and chronic infection with P. aeruginosa, although the method used was not reported.
Analysis of effectiveness
All of the patients included in the study were accounted for in the analysis. The primary health outcomes assessed were lung function and body weight. These were reported as the change in the average value between the year before and after TNS treatment (for the within-group comparisons), and as the difference between the average change experienced by the TNS patients and by the control patients (which was defined as the net effect). Lung function was measured by percentage forced expiratory volume in one second (FEV1%), while body weight was measured by standard deviation (SD) scores. Some of the resources used were reported as a proxy of effectiveness outcomes in the study: The results from within-group comparisons were also reported for the sub-group of patients aged less than 18 years.
At the start of the trial, the TNS-treated group and the control group of 30 matched pairs were shown to be comparable in terms of FEV1%, age and gender, although they were not comparable in prior use of antibiotics and hospital admissions. The TNS group received more inhaled antibiotics and had more admissions in the year before TNS administration.
Effectiveness results
The results from the between-group analysis showed that the mean FEV1% in both groups decreased with a net effect of +0.27 (95% confidence interval, CI: -2.86 -+3.40) in favour of TNS patients. The mean body weight in both groups increased with a net effect of +0.09 (95% CI: -0.18 -+0.32) for TNS patients. There was a reduction in the mean total number of days in hospital in both groups, but the results were affected by an outlier in the control group (net effect +2.4, 95% CI: -10.6 -+33.3). Both groups showed a reduction in the number of clinic attendances (net effect -1.46, 95% CI: -5.86 -+1.79) and ward admissions (net effect -0.34, 95% CI: -1.31 -+0.58). The TNS group had a decreased number of outpatient visits (net effect -0.42, 95% CI: -1.33 -+0.07) and IV courses (net effect -1.27, 95% CI: -2.28 --0.34), but increases were observed for the control groups. The TNS group had a slight increase in ICU admission, whereas there was a decrease in the control group (net effect +0.08, 95% CI: -0.27 -+0.53). None of these differences were statistically significant. There was a reduction of 24.1 days of IV antibiotic treatment in the TNS group, with no change in the controls, and this was statistically significant (net effect -23.3, 95% CI: -37.6 --11.4; p<0.001).
The within-group analysis showed that lung function declined, with a difference between the mean FEV1% scores in the year before and after TNS treatment of -1.26 (95% CI: -3.34 -+0.83). The mean weight SD scores increased by +0.07 (95% CI: -0.08 -+0.23). Reductions were observed in the number of days in hospital (mean -7.8, 95% CI: -13.0 --3.2) the number of days of IV administration (mean -16.4, 95% CI: -27.4 --7.9), the number of clinics attended (mean -1.95, 95% CI: -5.43 --0.29), the number of IV courses (mean -0.98, 95% CI: -1.71 --0.45), and the number of ward admissions (mean -0.83, 95% CI: -1.52 --0.32). There was no change in the number of outpatient visits (mean 0, 95% CI: -0.66 -+0.85), but there was an increase in the number of ICU admissions (mean +0.05, 95% CI: -0.20 -+0.59).
In the sub-analysis of the younger patients, the mean FEV1% scores increased by +0.19 (95% CI: -3.44 -+3.82) and the mean weight SD scores increased by +0.07 (95% CI: -0.08 -+0.23). 
Clinical conclusions
There was a greater reduction in lung volume function for patients in the control group over the study period, although this was not significant. A reduction in lung volume was also observed in the TNS group after TNS treatment, in comparison with the period before treatment, although the change was not significant. No significant differences in weight changes were found in either between-group or within-group comparisons. A larger clinical benefit was observed in the sub-set of younger patients.
Measure of benefits used in the economic analysis
The authors did not derive a summary measure of benefit. In effect, a cost-consequences analysis was performed.
Direct costs
Although the perspective used for the economic analysis was not reported, health service costs appear to have been analysed. These included the costs of TNS, drugs (antibiotics and other drugs) and hospitalisation (both ward and ICU), as well as costs related to other health care interventions (such as intercurrent illnesses and surgical procedures). The costs and the mean resource quantities used were reported separately. The resource quantities were obtained from medical records, while the unit costs were extracted from National Health Service (NHS) reference data.
The cost analysis was only undertaken on the 41 patients who received the intervention and on the sub-set of 19 patients aged less than 18 years. The time horizon used for the estimation of costs was 1 year for each of the treatment strategies considered (TNS versus previous treatment). Hence, discounting was correctly not applied. The average costs per patient were reported. The date of the price data was 2001. The authors stated that they made some adjustments so as to estimate one-year costs for those patients with a shorter follow-up. They scaled up the costs on a pro-rata basis.
Statistical analysis of costs
The data were treated as stochastic. Uncertainty in the resource use and cost measures was addressed using the nonparametric Bootstrap Bca method to establish 95% CIs.
Indirect Costs
The indirect costs were not reported.
Currency

UK pounds sterling ().
Sensitivity analysis
No sensitivity analysis was undertaken.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The mean total cost per patient was 28,394 in the year in which TNS was administered and 22,102 in the year preceding TNS treatment. This represented a mean difference of 6,292 (95% CI: +3,138 -+9,193).
For the sub-group of younger patients, the mean total cost per patient was 28,080 in the year in which TNS was administered and 24,250 in the year preceding TNS treatment. This represented a mean difference of 3,830 (95% CI: -1,165 -+6,805).
The cost of adverse effects was not specifically addressed.
Synthesis of costs and benefits
Not applicable because, in effect, a cost-consequences analysis was performed.
